EXPERT PANEL PRESENTATION

Efficacy and Safety of Aflibercept 8 mg in Previously Treated Patients With nAMD or DME: 24-Week Results From the Phase 3b ELARA Trial

Eric Schneider, MD, on behalf of the ELARA study investigators

Tennessee Retina PC, Nashville, TN, USA

Financial Disclosures:
Eric Schneider served as a consultant/advisor for Apellis, Astellas, Boehringer Ingelheim, Carl Zeiss Meditec, Notal Vision, Ollin Biosciences, and Regeneron Pharmaceuticals, Inc.; and received grant support from AffaMed Therapeutics, Apellis, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Cognition Therapeutics, Notal Vision, Oculis, and Regeneron Pharmaceuticals, Inc.

METHODS

Study eyes (N=1110) previously treated with ≥3 anti-VEGF injections within 5 months prior to study start in:

nAMD (n=622)
Patients aged ≥50 years with CNV lesions due to nAMD

DME (n=488)
Patients aged ≥18 years with center-involved DME

ELARA Study Design

1110 patients enrolled across 53 US sites



[a]DRM-E: Interval Extension

- **nAMD**
  - No retinal fluid in central subfield **AND**
  - No new-onset foveal neovascularization or hemorrhage **AND**
  - No interval shortening within the prior 12 weeks
- **DME**
  - CST <300 µm (or <320 µm on Spectralis) **AND**
  - ≤10-µm increase from lowest previous CST value **AND**
  - No interval shortening within the prior 12 weeks
- Intervals are extended in **1-week or 2-week increments** based on response to treatment

[b]DRM-S: Interval Shortening

- **nAMD**
  - Any new retinal fluid in central subfield **OR**
  - New-onset foveal neovascularization or hemorrhage **OR**
  - >5-letter loss in BCVA from best previous value
- **DME**
  - >25-µm increase in CST from previous visit **OR**
  - >10-letter loss in BCVA from best previous value
- Intervals are shortened in **1-week increments**
- The minimum interval is Q4

BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CST, central subfield thickness; DME, diabetic macular edema; DRM, dose regimen modification; EOS, end of study; EP, endpoint; nAMD, neovascular age-related macular degeneration; T&E, treat and extend; VEGF, vascular endothelial growth factor.

RESULTS

Mean Change in BCVA and CST in Patients With nAMD (n=622)



32.9% of patients gained ≥5 letters at Week 24, and patients received a mean of 6.0 injections through Week 24

SAF, observed cases.

Mean Change in BCVA and CST in Patients With DME (n=488)



36.8% of patients gained ≥5 letters at Week 24, and patients received a mean of 5.8 injections through Week 24

SAF, observed cases.

BL, baseline; ETDRS, Early Treatment Diabetic Retinopathy Study; IOI, intraocular inflammation; IOP, intraocular pressure; SAF, safety analysis set; TEAE, treatment-emergent adverse event.
[a]At any visit. [b]All events.

Ocular Safety in the Study Eye Through Week 24

	nAMD (n=622)	DME (n=488)	Total (N=1110)
Patients with ≥1 ocular TEAE, n (%)	106 (17.0)	109 (22.3)	215 (19.4)
Patients with ≥1 serious ocular TEAE, n (%)	1 (0.2)	4 (0.8)	5 (0.5)
Patients with ≥1 IOI TEAE, n (%)	6 (1.0)	5 (1.0)	11 (1.0)

SAF.

Intraocular Pressure in the Study Eye Through Week 24

	nAMD (n=622)	DME (n=488)	Total (N=1110)
Patients with ≥10 mmHg increase in pre-dose IOP from baseline[a]	16/616 (2.6%)	15/486 (3.1%)	31/1102 (2.8%)
Patients with pre-dose IOP ≥25 mmHg[a]	10/622 (1.6%)	13/488 (2.7%)	23/1110 (2.1%)
Patients with pre- or post-dose IOP ≥35 mmHg[a]	1/622 (0.2%)	4/488 (0.8%)	5/1110 (0.5%)

No clinically relevant change was observed over time in pre-dose IOP in all patients

SAF.

Non-ocular Safety Through Week 24

	nAMD (n=622)	DME (n=488)	Total (N=1110)
Patients with ≥1 serious non-ocular TEAE, n (%)	31 (5.0)	35 (7.2)	66 (5.9)
Patients with ≥1 hypertension-related TEAE, n (%)	22 (3.5)	14 (2.9)	36 (3.2)
Death, n (%)[b]	2 (0.3)	4 (0.8)	6 (0.5)

SAF.

DISCUSSION

- Aflibercept 8 mg every 4 weeks achieved meaningful functional and anatomic improvements at Week 24 in patients previously treated with anti-VEGF agents for nAMD or DME
- The safety profile of monthly dosing with aflibercept 8 mg through Week 24 was consistent with the established safety profile of both aflibercept 2 mg and 8 mg
  - No clinically relevant change was observed in pre-dose IOP with aflibercept 8 mg every 4 weeks
  - Incidence of hypertension events and death was low and consistent with that of prior aflibercept trials



SAF, observed cases.

ADDITIONAL BACK-UP DATA



Number of Previous Anti-VEGF Injections in Study Eye 6 Months Prior to Study Start

	nAMD (n=622)	DME[a] (n=488)	Total (N=1110)
Patients with ≥3 anti-VEGF injections in the study eye in prior 6 months, n (%)			
3 injections	181 (29.1)	195 (40.0)	376 (33.9)
4 injections	212 (34.1)	175 (35.9)	387 (34.9)
5 injections	168 (27.0)	97 (19.9)	265 (23.9)
6 injections	48 (7.7)	11 (2.3)	59 (5.3)
≥7 injections	8 (1.3)	1 (0.2)	9 (0.8)

SAF.
[a]Data for 1 patient in the DME cohort were missing.
[b]Ranibizumab or ranibizumab biosimilar (ranibizumab-eqrn or ranibizumab-nuna).